O	0	8	Androgen	Androgen	NN	B-NP
O	9	19	stimulates	stimulate	VBZ	B-VP
O	20	30	glycolysis	glycolysis	NN	B-NP
O	31	34	for	for	IN	B-PP
O	35	37	de	de	FW	B-NP
O	38	42	novo	novo	FW	I-NP
O	43	48	lipid	lipid	NN	I-NP
O	49	58	synthesis	synthesis	NN	I-NP
O	59	61	by	by	IN	B-PP
O	62	72	increasing	increase	VBG	B-VP
O	73	76	the	the	DT	B-NP
O	77	87	activities	activity	NNS	I-NP
O	88	90	of	of	IN	B-PP
O	91	101	hexokinase	hexokinase	NN	B-NP
O	102	103	2	2	CD	I-NP
O	104	107	and	and	CC	I-NP
O	108	109	6	6	CD	I-NP
O	109	110	-	-	HYPH	B-NP
O	110	123	phosphofructo	phosphofructo	AFX	I-NP
O	123	124	-	-	HYPH	I-NP
O	124	125	2	2	CD	I-NP
O	125	126	-	-	HYPH	I-NP
O	126	132	kinase	kinase	NN	I-NP
O	132	133	/	/	SYM	B-NP
O	133	141	fructose	fructose	NN	I-NP
O	141	142	-	-	HYPH	B-NP
O	142	143	2	2	CD	I-NP
O	143	144	,	,	,	I-NP
O	144	145	6	6	CD	I-NP
O	145	146	-	-	HYPH	I-NP
O	146	160	bisphosphatase	bisphosphatase	NN	I-NP
O	161	162	2	2	CD	I-NP
O	163	165	in	in	IN	B-PP
B-Cell	166	174	prostate	prostate	NN	B-NP
I-Cell	175	181	cancer	cancer	NN	I-NP
I-Cell	182	187	cells	cell	NNS	I-NP
O	187	188	.	.	.	O

O	190	192	Up	Up	RB	B-ADVP
O	192	193	-	-	HYPH	O
O	193	203	regulation	regulation	NN	B-NP
O	204	206	of	of	IN	B-PP
O	207	218	lipogenesis	lipogenesis	NN	B-NP
O	219	221	by	by	IN	B-PP
O	222	230	androgen	androgen	NN	B-NP
O	231	233	is	be	VBZ	B-VP
O	234	237	one	one	CD	B-NP
O	238	240	of	of	IN	B-PP
O	241	244	the	the	DT	B-NP
O	245	249	most	most	RBS	I-NP
O	250	264	characteristic	characteristic	JJ	I-NP
O	265	274	metabolic	metabolic	JJ	I-NP
O	275	283	features	feature	NNS	I-NP
O	284	286	of	of	IN	B-PP
B-Cell	287	292	LNCaP	LNCaP	NN	B-NP
I-Cell	293	301	prostate	prostate	NN	I-NP
I-Cell	302	308	cancer	cancer	NN	I-NP
I-Cell	309	314	cells	cell	NNS	I-NP
O	314	315	.	.	.	O

O	316	319	The	The	DT	B-NP
O	320	327	present	present	JJ	I-NP
O	328	333	study	study	NN	I-NP
O	334	342	revealed	reveal	VBD	B-VP
O	343	347	that	that	IN	B-SBAR
O	348	356	androgen	androgen	NN	B-NP
O	357	366	increases	increase	VBZ	B-VP
O	367	374	glucose	glucose	NN	B-NP
O	375	386	utilization	utilization	NN	I-NP
O	387	390	for	for	IN	B-PP
O	391	393	de	de	FW	B-NP
O	394	398	novo	novo	FW	I-NP
O	399	410	lipogenesis	lipogenesis	NN	I-NP
O	411	413	in	in	IN	B-PP
B-Cell	414	419	LNCaP	LNCaP	NN	B-NP
I-Cell	420	425	cells	cell	NNS	I-NP
O	426	433	through	through	IN	B-PP
O	434	437	the	the	DT	B-NP
O	438	448	activation	activation	NN	I-NP
O	449	451	of	of	IN	B-PP
O	452	455	HK2	HK2	NN	B-NP
O	456	457	(	(	(	O
O	457	467	hexokinase	hexokinase	NN	B-NP
O	468	469	2	2	CD	I-NP
O	469	470	)	)	)	O
O	471	474	and	and	CC	O
O	475	485	activation	activation	NN	B-NP
O	486	488	of	of	IN	B-PP
O	489	492	the	the	DT	B-NP
B-Organ	493	500	cardiac	cardiac	JJ	I-NP
O	501	508	isoform	isoform	NN	I-NP
O	509	511	of	of	IN	B-PP
O	512	518	PFKFB2	PFKFB2	NN	B-NP
O	519	520	(	(	(	O
O	520	521	6	6	CD	B-NP
O	521	522	-	-	HYPH	O
O	522	535	phosphofructo	phosphofructo	AFX	O
O	535	536	-	-	HYPH	B-NP
O	536	537	2	2	CD	I-NP
O	537	538	-	-	HYPH	I-NP
O	538	544	kinase	kinase	NN	I-NP
O	544	545	/	/	SYM	B-NP
O	545	553	fructose	fructose	NN	I-NP
O	553	554	-	-	HYPH	B-NP
O	554	555	2	2	CD	I-NP
O	555	556	,	,	,	I-NP
O	556	557	6	6	CD	I-NP
O	557	558	-	-	HYPH	I-NP
O	558	572	bisphosphatase	bisphosphatase	NN	I-NP
O	572	573	)	)	)	O
O	573	574	.	.	.	O

O	575	585	Activation	Activation	NN	B-NP
O	586	588	of	of	IN	B-PP
O	589	592	PKA	PKA	NN	B-NP
O	593	594	(	(	(	O
O	594	598	cAMP	cAMP	NN	B-NP
O	598	599	-	-	HYPH	B-NP
O	599	608	dependent	dependent	JJ	I-NP
O	609	616	protein	protein	NN	I-NP
O	617	623	kinase	kinase	NN	I-NP
O	623	624	)	)	)	O
O	625	627	by	by	IN	B-PP
O	628	636	androgen	androgen	NN	B-NP
O	637	646	increased	increase	VBD	B-VP
O	647	662	phosphorylation	phosphorylation	NN	B-NP
O	663	665	of	of	IN	B-PP
O	666	670	CREB	CREB	NN	B-NP
O	671	672	[	[	(	O
O	672	675	CRE	CRE	NN	B-NP
O	676	677	(	(	(	O
O	677	681	cAMP	cAMP	NN	B-NP
O	681	682	-	-	HYPH	O
O	682	690	response	response	NN	B-NP
O	691	698	element	element	NN	I-NP
O	698	699	)	)	)	O
O	699	700	-	-	HYPH	O
O	700	707	binding	bind	VBG	B-NP
O	708	715	protein	protein	NN	I-NP
O	715	716	]	]	)	O
O	716	717	,	,	,	O
O	718	723	which	which	WDT	B-NP
O	724	726	in	in	IN	B-PP
O	727	731	turn	turn	NN	B-NP
O	732	737	bound	bind	VBD	B-VP
O	738	740	to	to	TO	B-PP
O	741	744	CRE	CRE	NN	B-NP
O	745	747	on	on	IN	B-PP
O	748	751	the	the	DT	B-NP
O	752	760	promoter	promoter	NN	I-NP
O	761	763	of	of	IN	B-PP
O	764	767	the	the	DT	B-NP
O	768	771	HK2	HK2	NN	I-NP
O	772	776	gene	gene	NN	I-NP
O	777	786	resulting	result	VBG	B-VP
O	787	789	in	in	IN	B-PP
O	790	805	transcriptional	transcriptional	JJ	B-NP
O	806	816	activation	activation	NN	I-NP
O	817	819	of	of	IN	B-PP
O	820	823	the	the	DT	B-NP
O	824	827	HK2	HK2	NN	I-NP
O	828	832	gene	gene	NN	I-NP
O	832	833	.	.	.	O

O	834	836	Up	Up	RB	B-ADVP
O	836	837	-	-	HYPH	O
O	837	847	regulation	regulation	NN	B-NP
O	848	850	of	of	IN	B-PP
O	851	857	PFKFB2	PFKFB2	NN	B-NP
O	858	868	expression	expression	NN	I-NP
O	869	872	was	be	VBD	B-VP
O	873	881	mediated	mediate	VBN	I-VP
O	882	884	by	by	IN	B-PP
O	885	888	the	the	DT	B-NP
O	889	895	direct	direct	JJ	I-NP
O	896	903	binding	binding	NN	I-NP
O	904	906	of	of	IN	B-PP
O	907	913	ligand	ligand	NN	B-NP
O	913	914	-	-	HYPH	B-NP
O	914	923	activated	activate	VBN	I-NP
O	924	932	androgen	androgen	NN	I-NP
O	933	941	receptor	receptor	NN	I-NP
O	942	944	to	to	TO	B-PP
O	945	948	the	the	DT	B-NP
O	949	955	PFKFB2	PFKFB2	NN	I-NP
O	956	964	promoter	promoter	NN	I-NP
O	964	965	.	.	.	O

O	966	969	The	The	DT	B-NP
O	970	979	activated	activate	VBN	I-NP
O	980	984	PI3K	PI3K	NN	I-NP
O	985	986	(	(	(	O
O	986	1002	phosphoinositide	phosphoinositide	NN	B-NP
O	1003	1004	3	3	CD	I-NP
O	1004	1005	-	-	HYPH	I-NP
O	1005	1011	kinase	kinase	NN	I-NP
O	1011	1012	)	)	)	O
O	1012	1013	/	/	SYM	B-NP
O	1013	1016	Akt	Akt	NN	I-NP
O	1017	1027	signalling	signalling	NN	I-NP
O	1028	1035	pathway	pathway	NN	I-NP
O	1036	1038	in	in	IN	B-PP
B-Cell	1039	1044	LNCaP	LNCaP	NN	B-NP
I-Cell	1045	1050	cells	cell	NNS	I-NP
O	1051	1062	contributes	contribute	VBZ	B-VP
O	1063	1065	to	to	TO	B-PP
O	1066	1069	the	the	DT	B-NP
O	1070	1085	phosphorylation	phosphorylation	NN	I-NP
O	1086	1088	of	of	IN	B-PP
O	1089	1095	PFKFB2	PFKFB2	NN	B-NP
O	1096	1098	at	at	IN	B-PP
O	1099	1105	Ser466	Ser466	NN	B-NP
O	1106	1109	and	and	CC	I-NP
O	1110	1116	Ser483	Ser483	NN	I-NP
O	1116	1117	,	,	,	O
O	1118	1127	resulting	result	VBG	B-VP
O	1128	1130	in	in	IN	B-PP
O	1131	1134	the	the	DT	B-NP
O	1135	1147	constitutive	constitutive	JJ	I-NP
O	1148	1158	activation	activation	NN	I-NP
O	1159	1161	of	of	IN	B-PP
O	1162	1165	PFK	PFK	NN	B-NP
O	1165	1166	-	-	HYPH	O
O	1166	1167	2	2	CD	B-NP
O	1168	1169	(	(	(	O
O	1169	1170	6	6	CD	B-NP
O	1170	1171	-	-	HYPH	O
O	1171	1184	phosphofructo	phosphofructo	AFX	O
O	1184	1185	-	-	HYPH	B-NP
O	1185	1186	2	2	CD	I-NP
O	1186	1187	-	-	HYPH	I-NP
O	1187	1193	kinase	kinase	NN	I-NP
O	1193	1194	)	)	)	O
O	1195	1203	activity	activity	NN	B-NP
O	1203	1204	.	.	.	O

O	1205	1212	Glucose	Glucose	NN	B-NP
O	1213	1219	uptake	uptake	NN	I-NP
O	1220	1223	and	and	CC	I-NP
O	1224	1235	lipogenesis	lipogenesis	NN	I-NP
O	1236	1240	were	be	VBD	B-VP
O	1241	1249	severely	severely	RB	I-VP
O	1250	1257	blocked	block	VBN	I-VP
O	1258	1260	by	by	IN	B-PP
O	1261	1269	knocking	knock	VBG	B-VP
O	1269	1270	-	-	HYPH	B-NP
O	1270	1274	down	down	RB	B-ADVP
O	1275	1277	of	of	IN	B-PP
O	1278	1284	PFKFB2	PFKFB2	NN	B-NP
O	1285	1290	using	use	VBG	B-VP
O	1291	1296	siRNA	siRNA	NN	B-NP
O	1297	1298	(	(	(	O
O	1298	1303	small	small	JJ	B-NP
O	1304	1315	interfering	interfere	VBG	I-NP
O	1316	1319	RNA	RNA	NN	I-NP
O	1319	1320	)	)	)	O
O	1321	1323	or	or	CC	O
O	1324	1326	by	by	IN	B-PP
O	1327	1337	inhibition	inhibition	NN	B-NP
O	1338	1340	of	of	IN	B-PP
O	1341	1344	PFK	PFK	NN	B-NP
O	1344	1345	-	-	HYPH	O
O	1345	1346	2	2	CD	B-NP
O	1347	1355	activity	activity	NN	I-NP
O	1356	1360	with	with	IN	B-PP
O	1361	1369	LY294002	LY294002	NN	B-NP
O	1370	1379	treatment	treatment	NN	I-NP
O	1379	1380	.	.	.	O

O	1381	1386	Taken	Take	VBN	B-VP
O	1387	1395	together	together	RB	B-ADVP
O	1395	1396	,	,	,	O
O	1397	1400	our	our	PRP$	B-NP
O	1401	1408	results	result	NNS	I-NP
O	1409	1416	suggest	suggest	VBP	B-VP
O	1417	1421	that	that	IN	B-SBAR
O	1422	1425	the	the	DT	B-NP
O	1426	1435	induction	induction	NN	I-NP
O	1436	1438	of	of	IN	B-PP
O	1439	1441	de	de	FW	B-NP
O	1442	1446	novo	novo	FW	I-NP
O	1447	1452	lipid	lipid	NN	I-NP
O	1453	1462	synthesis	synthesis	NN	I-NP
O	1463	1465	by	by	IN	B-PP
O	1466	1474	androgen	androgen	NN	B-NP
O	1475	1483	requires	require	VBZ	B-VP
O	1484	1487	the	the	DT	B-NP
O	1488	1503	transcriptional	transcriptional	JJ	I-NP
O	1504	1506	up	up	RB	B-ADVP
O	1506	1507	-	-	HYPH	O
O	1507	1517	regulation	regulation	NN	B-NP
O	1518	1520	of	of	IN	B-PP
O	1521	1524	HK2	HK2	NN	B-NP
O	1525	1528	and	and	CC	I-NP
O	1529	1535	PFKFB2	PFKFB2	NN	I-NP
O	1535	1536	,	,	,	O
O	1537	1540	and	and	CC	O
O	1541	1556	phosphorylation	phosphorylation	NN	B-NP
O	1557	1559	of	of	IN	B-PP
O	1560	1566	PFKFB2	PFKFB2	NN	B-NP
O	1567	1576	generated	generate	VBN	B-VP
O	1577	1579	by	by	IN	B-PP
O	1580	1583	the	the	DT	B-NP
O	1584	1588	PI3K	PI3K	NN	I-NP
O	1588	1589	/	/	SYM	B-NP
O	1589	1592	Akt	Akt	NN	I-NP
O	1593	1603	signalling	signalling	NN	I-NP
O	1604	1611	pathway	pathway	NN	I-NP
O	1612	1614	to	to	TO	B-VP
O	1615	1621	supply	supply	VB	I-VP
O	1622	1625	the	the	DT	B-NP
O	1626	1632	source	source	NN	I-NP
O	1633	1636	for	for	IN	B-PP
O	1637	1648	lipogenesis	lipogenesis	NN	B-NP
O	1649	1653	from	from	IN	B-PP
O	1654	1661	glucose	glucose	NN	B-NP
O	1662	1664	in	in	IN	B-PP
B-Cell	1665	1673	prostate	prostate	NN	B-NP
I-Cell	1674	1680	cancer	cancer	NN	I-NP
I-Cell	1681	1686	cells	cell	NNS	I-NP
O	1686	1687	.	.	.	O

